AVS Bio Acquires ImmunoPrecise Antibodies (Europe) B.V.

ImmunoPrecise Antibodies Acquires Belgian BioStrand, BioKey and BioClue

April 14, 2022

Biotechnology

ImmunoPrecise Antibodies Ltd. (IPA), through its subsidiary ImmunoPrecise Netherlands BV, completed the acquisition of BioStrand BV, BioKey BV and BioClue BV, a group of Belgian bioinformatics and biotech companies. The deal (approx. €20 million consideration plus up to €12 million earnout and a €6 million investment commitment) adds AI-driven multi-omics analytics and software capabilities to IPA's antibody discovery and biotherapeutics platform.

BioIVT Acquires PrecisionMed

July 18, 2023

Healthcare Services

BioIVT, a global biospecimen solutions provider, has acquired PrecisionMed, LLC, a Carlsbad-based supplier of high-quality human biospecimens and owner of a large longitudinal cerebrospinal fluid (CSF) repository. The acquisition expands BioIVT's supply network, inventory and capacity for CSF and liquid biopsy products while PrecisionMed will continue to operate from its existing headquarters and collection sites.

Arlington Capital Partners Acquires Charles River's Avian Vaccine Services to Form AVS Bio

January 5, 2023

Biotechnology

Arlington Capital Partners has acquired Charles River Laboratories' Avian Vaccine Services business to form a standalone company, AVS Bio, serving the biologic manufacturing and bioprocessing markets. AVS Bio, headquartered in Norwich, Connecticut, supplies SPF eggs, antigens, cell products and diagnostic/manufacturing support services and has ~250 employees across 20+ facilities; Fairmount Partners advised Charles River on the sale.

Twist Bioscience Acquires Abveris

November 22, 2021

Biotechnology

Twist Bioscience entered into a definitive agreement to acquire Abveris (formerly AbX Biologics), an in vivo antibody discovery services company, for up to $190 million. The deal (approximately $150 million at closing in Twist common stock and up to $40 million contingent stock consideration plus limited cash) is intended to combine Abveris's mouse-based discovery platform with Twist's humanization and antibody engineering capabilities to broaden Twist's antibody discovery and biopharma services.

Biosynth Carbosynth Acquires Aalto Bio Reagents

May 26, 2022

Biotechnology

Biosynth Carbosynth, a Swiss life‑sciences supplier, has acquired Aalto Bio Reagents, a Dublin‑based developer and provider of biological materials for in‑vitro diagnostics (IVD) and vaccine development. The deal strengthens Biosynth’s IVD and vaccine product portfolio and expands its capabilities to serve diagnostics and vaccine development customers worldwide.

Vertex Pharmaceuticals Acquires Alpine Immune Sciences

April 10, 2024

Biotechnology

Vertex Pharmaceuticals will acquire Alpine Immune Sciences for $65 per share (approximately $4.9 billion) in cash. The acquisition adds Alpine’s lead candidate povetacicept (ALPN‑303) and protein-engineering/immunotherapy capabilities to Vertex’s pipeline and is expected to close in Q2 2024, subject to customary conditions.